With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
169447-70-5, Step 1: (S)-tert-butyl 4-(4-fluorophenyl)-2-methylpiperazine-1-carboxylate A solution of (S)-tert-butyl 2-methylpiperazine-1-carboxylate (1.2 g, 6 mmol), 1-bromo-4-fluorobenzene (1.26 g, 7.2 mmol), t-BuONa (865 mg, 9 mmol), BINAP (150 mg, 0.24 mmol), Pd2 (dba)3 (110 mg, 0.12 mmol) in dry toluene (40 mL) was stirred under N2 at 80 C. for 16 hrs. The reaction mixture was concentrated and the residue was purified by chromatography (silica, EtOAc/PE=1/10) to afford (S)-tert-butyl-4-(4-fluorophenyl)-2-methylpiperazine-1-carboxylate (1.5 g, 5.1 mmol, 85%) as a yellow oil. ESI-MS (EI+, m/z): 295.1 [M+H]+.
As the paragraph descriping shows that 169447-70-5 is playing an increasingly important role.
Reference：
Patent; Navitor Pharmaceuticals, Inc.; O’Neill, David John; Saiah, Eddine; Kang, Seong Woo Anthony; Brearley, Andrew; Bentley, Jonathan; (136 pag.)US2019/389843; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics